Assertio (ASRT) Competitors $0.89 +0.04 (+5.09%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ASRT vs. BTMD, DSGN, VYGR, CTNM, SLRN, KMDA, CGC, TRVI, AQST, and ETONShould you be buying Assertio stock or one of its competitors? The main competitors of Assertio include biote (BTMD), Design Therapeutics (DSGN), Voyager Therapeutics (VYGR), Contineum Therapeutics (CTNM), Acelyrin (SLRN), Kamada (KMDA), Canopy Growth (CGC), Trevi Therapeutics (TRVI), Aquestive Therapeutics (AQST), and Eton Pharmaceuticals (ETON). These companies are all part of the "pharmaceutical products" industry. Assertio vs. biote Design Therapeutics Voyager Therapeutics Contineum Therapeutics Acelyrin Kamada Canopy Growth Trevi Therapeutics Aquestive Therapeutics Eton Pharmaceuticals biote (NASDAQ:BTMD) and Assertio (NASDAQ:ASRT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability, community ranking and analyst recommendations. Do institutionals & insiders have more ownership in BTMD or ASRT? 21.7% of biote shares are held by institutional investors. Comparatively, 49.0% of Assertio shares are held by institutional investors. 13.9% of biote shares are held by insiders. Comparatively, 3.2% of Assertio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts prefer BTMD or ASRT? biote presently has a consensus target price of $9.11, suggesting a potential upside of 49.34%. Assertio has a consensus target price of $3.25, suggesting a potential upside of 266.86%. Given Assertio's higher probable upside, analysts clearly believe Assertio is more favorable than biote.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score biote 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Assertio 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer BTMD or ASRT? Assertio received 96 more outperform votes than biote when rated by MarketBeat users. However, 100.00% of users gave biote an outperform vote while only 60.11% of users gave Assertio an outperform vote. CompanyUnderperformOutperformbioteOutperform Votes14100.00% Underperform VotesNo VotesAssertioOutperform Votes11060.11% Underperform Votes7339.89% Which has stronger valuation and earnings, BTMD or ASRT? biote has higher revenue and earnings than Assertio. Assertio is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratiobiote$193.06M1.72$3.32M$0.2623.46Assertio$125.76M0.67-$331.94M-$0.73-1.21 Does the media favor BTMD or ASRT? In the previous week, Assertio had 2 more articles in the media than biote. MarketBeat recorded 7 mentions for Assertio and 5 mentions for biote. biote's average media sentiment score of 0.79 beat Assertio's score of 0.36 indicating that biote is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment biote 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Assertio 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is BTMD or ASRT more profitable? biote has a net margin of 5.20% compared to Assertio's net margin of -54.46%. Assertio's return on equity of 3.79% beat biote's return on equity.Company Net Margins Return on Equity Return on Assets biote5.20% -32.41% 22.26% Assertio -54.46%3.79%1.81% Which has more volatility and risk, BTMD or ASRT? biote has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Comparatively, Assertio has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Summarybiote beats Assertio on 12 of the 17 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Assertio News Delivered to You Automatically Sign up to receive the latest news and ratings for ASRT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ASRT vs. The Competition Export to ExcelMetricAssertioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$80.49M$6.57B$5.01B$9.08BDividend YieldN/A3.09%4.87%4.21%P/E Ratio-1.2110.55135.0717.15Price / Sales0.67195.041,120.63116.80Price / Cash1.3257.1640.5837.88Price / Book0.615.104.754.78Net Income-$331.94M$151.51M$118.50M$225.60M7 Day Performance-3.71%-2.13%-1.85%-1.21%1 Month Performance-8.26%-3.13%11.28%3.09%1 Year Performance-18.72%11.54%29.92%16.48% Assertio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ASRTAssertio3.3731 of 5 stars$0.89+5.1%$3.25+266.9%-14.8%$80.49M$125.76M-1.2120Gap DownBTMDbiote3.2446 of 5 stars$6.60+3.6%$9.11+38.0%+20.8%$358.62M$193.06M24.77194Positive NewsGap UpDSGNDesign Therapeutics0.926 of 5 stars$6.29+12.3%$7.00+11.3%+143.2%$356.15MN/A-7.1840News CoveragePositive NewsVYGRVoyager Therapeutics4.6047 of 5 stars$6.51+3.8%$17.00+161.1%-27.6%$355.64M$250.01M8.83100CTNMContineum Therapeutics1.9464 of 5 stars$13.68-2.5%$29.25+113.8%N/A$352.67M$50M0.0031News CoverageSLRNAcelyrin2.5887 of 5 stars$3.38+4.6%$11.75+247.6%-55.8%$339.12MN/A-1.31135KMDAKamada3.8898 of 5 stars$5.85-0.3%$14.50+147.9%-1.2%$336.26M$158.38M20.96360Positive NewsCGCCanopy Growth2.4388 of 5 stars$3.05-1.9%$3.50+14.8%-41.0%$332.27M$220.27M-0.631,029Analyst RevisionNews CoverageTRVITrevi Therapeutics3.0381 of 5 stars$4.30+3.1%$9.31+116.6%+214.0%$330.54MN/A-10.2020Gap DownHigh Trading VolumeAQSTAquestive Therapeutics1.4991 of 5 stars$3.61flat$9.80+171.5%+95.2%$329.16M$50.58M-8.02160Analyst ForecastAnalyst RevisionNews CoveragePositive NewsETONEton Pharmaceuticals2.139 of 5 stars$12.72+3.0%$15.00+17.9%+176.9%$328.69M$31.64M-56.1420 Related Companies and Tools Related Companies biote Competitors Design Therapeutics Competitors Voyager Therapeutics Competitors Contineum Therapeutics Competitors Acelyrin Competitors Kamada Competitors Canopy Growth Competitors Trevi Therapeutics Competitors Aquestive Therapeutics Competitors Eton Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ASRT) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Assertio Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Assertio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
